<DOC>
	<DOCNO>NCT01365000</DOCNO>
	<brief_summary>The assessment Relative Bioavailability NKTR-118 Three Formulations Healthy Subjects .</brief_summary>
	<brief_title>Assessment Relative Bioavailability NKTR-118 Three Formulations Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Provision sign date , write informed consent prior studyspecific procedure Females must negative pregnancy test screen admission unit , must lactate , must nonchildbearing potential , confirm screen fulfil one follow criterion : Postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment follicle stimulate hormone ( FSH ) level laboratory define postmenopausal range Irreversible surgical sterilization hysterectomy , bilateral oophorectomy , bilateral salpingectomy , tubal ligation Volunteers must body mass index ( BMI ) 18 30 kg/m2 weigh least 50 kg Volunteers must able understand willing comply study procedure , restriction requirement Healthy male nonfertile female volunteer age 18 55 year inclusive , suitable vein cannulation repeat venipuncture Any clinically significant disease disorder ( eg , cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment ) , opinion Investigator , may either put healthy volunteer risk participation study , influence absorption , distribution , metabolism , excretion drug Current smoker , smoke use nicotine product within previous 3 month date screening ( Visit 1 ) Plasma donation within 1 month screen blood donation/blood loss &gt; 500 mL 3 month prior screen intention donate blood blood product study within 3 month completion study Positive screen drug abuse , cotinine ( nicotine level 400 ng/mL ) , screen admission and/or positive alcohol test admission Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>NKTR-118</keyword>
	<keyword>fast feed state</keyword>
	<keyword>cross-over study</keyword>
	<keyword>AUC ( 0-t )</keyword>
	<keyword>Cmax</keyword>
	<keyword>tmax</keyword>
	<keyword>QTcF Interval</keyword>
</DOC>